Upjohn Company, Kalamazoo, Michigan 49001.
Low dose flunixin meglumine: Effects on eicosanoid production and clinical signs induced by experimental endotoxaemia in horses
Article first published online: 23 APR 2010
© 1987 EVJ Ltd
Equine Veterinary Journal
Volume 19, Issue 3, pages 201–206, May 1987
How to Cite
SEMRAD, S. D., HARDEE, G. E., HARDEE, M. M. and MOORE, J. N. (1987), Low dose flunixin meglumine: Effects on eicosanoid production and clinical signs induced by experimental endotoxaemia in horses. Equine Veterinary Journal, 19: 201–206. doi: 10.1111/j.2042-3306.1987.tb01380.x
- Issue published online: 23 APR 2010
- Article first published online: 23 APR 2010
- Received for publication 22.5.86; Accepted 30.7.86
The efficacy of low doses of flunixin meglumine in reducing eicosanoid generation and clinical signs in response to experimentally induced endotoxaemia was investigated. Thromboxane H2 and 6-keto-prostaglandin F1α were measured in serum and plasma by radioimmunoassay. Plasma flunixin concentrations were determined by high performance liquid chromatography and pharmacokinetic parameters derived non-compartmentally. In horses administered flunixin meglumine before endotoxin challenge, a significant suppression in plasma thromboxane B2 and 6-keto-prostaglandin F1α generation was observed. Elevations in blood lactate were significantly suppressed in horses pre-treated with 0.25 mg/kg bodyweight flunixin meglumine. Reduction of the clinical signs of endotoxaemia by flunixin meglumine was dose dependent. Low doses of flunixin inhibited eicosanoid production without masking all of the physical manifestations of endotoxaemia necessary for accurate clinical evaluation of the horse's status.